AstraZeneca in talks with Bristol Myers Squibb on potential megadeal, FT reports

• The combined entity would be valued at approximately $400 billion, making it one of the largest pharmaceutical groups globally
• Talks have taken place in recent months but remain uncertain, with the deal potentially materializing soon or falling apart
• This comes about 12 years after AstraZeneca successfully resisted a takeover attempt by Pfizer

Summary:

UK-based AstraZeneca is in discussions with U.S. pharmaceutical company Bristol Myers Squibb regarding a potential merger that would create one of the world's largest pharmaceutical groups, according to a Financial Times report citing sources familiar with the matter.

Key Details:

• Combined valuation: Nearly $400 billion
• Timeline: Talks have occurred in recent months; a deal could materialize soon but may also be delayed or fall apart
• Companies involved: AstraZeneca (UK) and Bristol Myers Squibb (U.S.)

Context:

This potential megadeal comes approximately 12 years after AstraZeneca successfully resisted a takeover attempt by Pfizer, a larger U.S. pharmaceutical competitor. Both companies declined to comment or did not immediately respond to Reuters' requests for verification.

Market Implications:

If completed, this merger would significantly reshape the global pharmaceutical landscape, creating a powerhouse that could rival the industry's largest players. The combined entity would have substantial scale advantages in research and development, manufacturing, and market reach across both European and American markets.

The pharmaceutical sector has seen consolidation as companies seek to strengthen their competitive positions, share R&D costs, and build diverse product portfolios. However, the uncertainty around deal completion—as noted in the report—suggests negotiations are ongoing and subject to various regulatory, financial, and strategic considerations.

Status: The deal remains speculative at this stage, with no official confirmation from either company. Investors should monitor for official announcements and regulatory filings for concrete developments.